Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites

(1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed. However, it is still unclear whether this novel drug may improve long-term survival rates in cirrhotic patients with ascites....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Med
Autors principals: Hosui, Atsushi, Tanimoto, Takafumi, Okahara, Toru, Ashida, Munehiro, Ohnishi, Kohsaku, Wakahara, Yuhhei, Kusumoto, Yukihiro, Yamaguchi, Toshio, Sueyoshi, Yuka, Hirao, Motohiro, Yamada, Takuya, Hiramatsu, Naoki
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7830941/
https://ncbi.nlm.nih.gov/pubmed/33466878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10020294
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars